Literature DB >> 11385303

NMP 22, BTA stat test and cytology in the diagnosis of bladder cancer: a comparative study.

J L Gutiérrez Baños1, M H Rebollo Rodrigo, F M Antolín Juárez, B Martín García.   

Abstract

OBJECTIVE: To evaluate the usefulness of the NMP 22 and BTA stat test in the diagnosis and follow-up of bladder cancer and to compare these tests to cytology and cystoscopy, routine diagnostic methods.
METHODS: 150 patients followed up for bladder cancer or symptoms suggestive of bladder cancer underwent cystoscopy after cytology, NMP 22 and BTA stat test using a recently voided urine sample. In suspect cases, TUR and histopathological analysis were performed.
RESULTS: Bladder cancer was proven in 76 patients and excluded in 74. For NMP 22 we have used the cutoff value recommended by the manufacturer (10 U/ml) and that obtained by our receiver-operating characteristic curve (6 U/ml). Sensitivity was 84.21% for NMP 22 at the cutoff value of 6 U/ml and 76.32% with 10 U/ml; 72.37% for BTA stat test; 69.74% for cytology, and 100% for cystoscopy. Specificity was 86.49% for NMP 22 at a cutoff value of 6 U/ml and 90.54% at 10 U/ml; 89.19% for the BTA stat test; 93.24% for cytology and 89.19% for cystoscopy. NMP 22 sensitivity for grades 1, 2, and 3 was 68.75, 75.86 and 100%, respectively, at a cutoff value of 6 U/ml, and 50, 68.97 and 96.77%, respectively, at a cutoff level of 10 U/ml; for BTA stat the sensitivity was 56.25% in G1, 62.07% in G2 and 90.32% in G3, and for cytology the sensitivity was 43.75, 62.07 and 90.32%, respectively. The sensitivity of NMP 22 was 68.75% in stage Ta, 84.78% in T1 and 100% in T2-T4 at a cutoff level of 6 U/ml and 50, 80.43 and 92.86%, respectively, at a cutoff level of 10 U/ml; BTA stat sensitivity was 50% in Ta, 73.91% in T1 and 92.86% in T2-T4; and in cytology the results were 37.50, 73.91 and 85.71%, respectively. Using the McNemar test, there was only a significant difference between the sensitivity of NMP 22 at a cutoff level of 6 U/ml and cytology in the overall sample.
CONCLUSIONS: The high sensitivity of the NMP 22 and BTA stat test in combination with the data obtained from the parameters used for the evaluation of the test demonstrate their usefulness in the diagnosis and follow-up of bladder cancer. NMP 22 at a cutoff value of 6 U/ml is significantly more sensitive than cytology and consequently a thoroughly valid diagnostic tool in the diagnosis of bladder cancer which may substitute voided urine cytology. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11385303     DOI: 10.1159/000056612

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  6 in total

1.  Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression.

Authors:  Adam S Feldman; Jacqueline Banyard; Chin-Lee Wu; W Scott McDougal; Bruce R Zetter
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

Review 2.  Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand?

Authors:  Samir P Shirodkar; Vinata B Lokeshwar
Journal:  Expert Rev Anticancer Ther       Date:  2008-07       Impact factor: 4.512

Review 3.  [Urine-based markers of angiogenesis in bladder cancer].

Authors:  M Becker; D Tilki; T Szarvas; H Rübben; S Ergün
Journal:  Urologe A       Date:  2009-06       Impact factor: 0.639

Review 4.  Defining the role of NMP22 in bladder cancer surveillance.

Authors:  Carvell T Nguyen; J Stephen Jones
Journal:  World J Urol       Date:  2007-12-04       Impact factor: 4.226

Review 5.  Comparison of the clinical usefulness of different urinary tests for the initial detection of bladder cancer: a systematic review.

Authors:  Alessandro Sciarra; Giovanni Di Lascio; Francesco Del Giudice; Pier Paolo Leoncini; Stefano Salciccia; Alessandro Gentilucci; Angelo Porreca; Benjamin I Chung; Giovanni Di Pierro; Gian Maria Busetto; Ettore De Berardinis; Martina Maggi
Journal:  Curr Urol       Date:  2021-03-29

6.  A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder Cancer.

Authors:  Jamie J D'Costa; James C Goldsmith; Jayne S Wilson; Richard T Bryan; Douglas G Ward
Journal:  Bladder Cancer       Date:  2016-07-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.